Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug shows promise for kidney and heart health in Non-Diabetic patients

NCT ID NCT07344922

Disease control Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether dapagliflozin, a drug typically used for diabetes, can slow kidney decline, improve anemia, and support heart health in 100 adults with chronic kidney disease who do not have diabetes. Participants took either the drug or a placebo daily for 12 months alongside their usual care. The goal is to find a new way to manage these conditions without relying on lifelong medications beyond the study period.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

100 people

The number who actually took part.

Started

Sep 2022

Finished

Dec 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years with a diagnosis of chronic kidney disease (CKD), non-diabetic etiology. * Estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m² at screening. * Stable standard CKD care for at least 3 months prior to enrollment. * Ability to provide written informed consent. Exclusion Criteria: * Diagnosis of diabetes mellitus (type 1 or type 2). * History of kidney transplantation or currently on dialysis. * Acute kidney injury within the past 3 months. * Known hypersensitivity to dapagliflozin or excipients. * Pregnant or breastfeeding women. * Participation in another interventional clinical trial within the past 30 days. * Severe uncontrolled cardiovascular disease (e.g., recent myocardial infarction, unstable angina, decompensated heart failure). * Any condition judged by the investigator to interfere with study participation or interpretation of results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anemia calcinosis chronic kidney disease chronic renal failure syndrome Vascular Calcification

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Cardiovascular calcification Chronic kidney disease

Contacts and locations

Locations

  • Urology and Nephrology Center, Mansoura University

    Al Mansurah, Dakahlia Governorate, 35511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.